The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy-Reference-Cited by-同舟云学术

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy

Published:2011-07 Issue:2 Volume:82 Page:122-130
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Wardell Suzanne E.,Marks Jeffrey R.,McDonnell Donald P.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference31 articles.

1. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor;Masri;Cancer Res,2008

2. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors;Dodwell;Breast,2006

3. Endocrine treatment options for advanced breast cancer—the role of fulvestrant;Robertson;Eur J Cancer,2005

4. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signaling and oestrogen receptor activity in clinical breast cancer;Gee;Endocrine Related Cancer,2005

5. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer;Shou;J Natl Cancer Inst,2004

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

2. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer;Future Oncology;2024-07-29

3. Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05

4. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer;European Journal of Medicinal Chemistry;2024-04

5. Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer;Cancers;2024-01-31